Asthma pathway (BTS, NICE, SIGN) [SIGN 244]

⚠️IMPORTANT⚠️

In April 2025 the MHRA issued a reminder of the risk of severe asthma attacks and increased mortality associated with overuse of SABA with or without anti-inflammatory maintenance therapy in patients with asthma.

Further information is available from: Short-acting beta 2 agonists (SABA) (salbutamol and terbutaline): reminder of the risks from overuse in asthma and to be aware of changes in the SABA prescribing guidelines